Juno Therapeutics Reports Third Quarter 2015 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/12/2026
- Nasdaq falls ahead of earnings, economic data while oil rallies
- Oil prices rise on Saudi Arabia attacks, overshadowing Trump's diesel deal
- Will surging equity supply derail the U.S. bull market? Goldman Sachs weighs in
- Broadcom CEO says many AI investors are gamblers
- "Not buying Chipotle": Starbucks squashes blockbuster acquisition speculation
- One dead in new attack on Saudi airport, a day after Houthi strike kills 13
- Bausch + Lomb names Appio interim CEO as Saunders departs
- Cerebras Systems hits new 52-week low on unlock concerns
- Getty Images to go private via prepackaged Chapter 11 restructuring
- Kroger (KR) To Cut Corporate Workforce By About 3,000 Over 3 Years - Bloomberg
Juno Therapeutics (JUNO) Misses Q3 EPS by 12c, Offers Guidance
November 10, 2015 4:07 PM ESTJuno Therapeutics (NASDAQ: JUNO) reported Q3 EPS of ($0.53), $0.12 worse than the analyst estimate of ($0.41). Revenue for the quarter came in at $1.6 million, versus $0 reported last year.
2015 Financial Guidance
Juno continues to expect 2015 cash burn, excluding cash inflows or outflows from business... More



